Literature DB >> 29444435

PTPN2 Regulates Inflammasome Activation and Controls Onset of Intestinal Inflammation and Colon Cancer.

Marianne R Spalinger1, Roberto Manzini1, Larissa Hering1, Julianne B Riggs1, Claudia Gottier1, Silvia Lang1, Kirstin Atrott1, Antonia Fettelschoss2, Florian Olomski2, Thomas M Kündig2, Michael Fried3, Declan F McCole4, Gerhard Rogler3, Michael Scharl5.   

Abstract

Variants in the gene locus encoding protein tyrosine phosphatase non-receptor type 2 (PTPN2) are associated with inflammatory disorders, including inflammatory bowel diseases, rheumatoid arthritis, and type 1 diabetes. The anti-inflammatory role of PTPN2 is highlighted by the fact that PTPN2-deficient mice die a few weeks after birth because of systemic inflammation and severe colitis. However, the tissues, cells, and molecular mechanisms that contribute to this phenotype remain unclear. Here, we demonstrate that myeloid cell-specific deletion of PTPN2 in mice (PTPN2-LysMCre) promotes intestinal inflammation but protects from colitis-associated tumor formation in an IL-1β-dependent manner. Elevated levels of mature IL-1β production in PTPN2-LysMCre mice are a consequence of increased inflammasome assembly due to elevated phosphorylation of the inflammasome adaptor molecule ASC. Thus, we have identified a dual role for myeloid PTPN2 in directly regulating inflammasome activation and IL-1β production to suppress pro-inflammatory responses during colitis but promote intestinal tumor development.
Copyright © 2018 The Author(s). Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  IBD; TC-PTP; colitis; inflammasome; inflammatory bowel disease; interleukin-1-alpha

Mesh:

Substances:

Year:  2018        PMID: 29444435      PMCID: PMC6636824          DOI: 10.1016/j.celrep.2018.01.052

Source DB:  PubMed          Journal:  Cell Rep            Impact factor:   9.423


  50 in total

Review 1.  Intestinal macrophages: well educated exceptions from the rule.

Authors:  Ehud Zigmond; Steffen Jung
Journal:  Trends Immunol       Date:  2013-03-13       Impact factor: 16.687

2.  Involvement of a calpain-like protease in the processing of the murine interleukin 1 alpha precursor.

Authors:  L M Carruth; S Demczuk; S B Mizel
Journal:  J Biol Chem       Date:  1991-07-05       Impact factor: 5.157

3.  Protein tyrosine phosphatase nonreceptor type 2: an important regulator of lnterleukin-6 production in rheumatoid arthritis synovial fibroblasts.

Authors:  Borbala Aradi; Masaru Kato; Maria Filkova; Emmanuel Karouzakis; Kerstin Klein; Michael Scharl; Christoph Kolling; Beat A Michel; Renate E Gay; Edit I Buzas; Steffen Gay; Astrid Jüngel
Journal:  Arthritis Rheumatol       Date:  2015-10       Impact factor: 10.995

4.  In vivo CRISPR screening identifies Ptpn2 as a cancer immunotherapy target.

Authors:  Robert T Manguso; Hans W Pope; Margaret D Zimmer; Flavian D Brown; Kathleen B Yates; Brian C Miller; Natalie B Collins; Kevin Bi; Martin W LaFleur; Vikram R Juneja; Sarah A Weiss; Jennifer Lo; David E Fisher; Diana Miao; Eliezer Van Allen; David E Root; Arlene H Sharpe; John G Doench; W Nicholas Haining
Journal:  Nature       Date:  2017-07-19       Impact factor: 49.962

5.  The NLRP3 inflammasome functions as a negative regulator of tumorigenesis during colitis-associated cancer.

Authors:  Irving C Allen; Erin McElvania TeKippe; Rita-Marie T Woodford; Joshua M Uronis; Eda K Holl; Arlin B Rogers; Hans H Herfarth; Christian Jobin; Jenny P-Y Ting
Journal:  J Exp Med       Date:  2010-04-12       Impact factor: 14.307

6.  Regulation of IL-8 and IL-1beta expression in Crohn's disease associated NOD2/CARD15 mutations.

Authors:  Jing Li; Thomas Moran; Eric Swanson; Christina Julian; Jeremy Harris; Denise K Bonen; Matija Hedl; Dan L Nicolae; Clara Abraham; Judy H Cho
Journal:  Hum Mol Genet       Date:  2004-06-15       Impact factor: 6.150

7.  Activation of the NLRP3 inflammasome in dendritic cells induces IL-1beta-dependent adaptive immunity against tumors.

Authors:  François Ghiringhelli; Lionel Apetoh; Antoine Tesniere; Laetitia Aymeric; Yuting Ma; Carla Ortiz; Karim Vermaelen; Theocharis Panaretakis; Grégoire Mignot; Evelyn Ullrich; Jean-Luc Perfettini; Frédéric Schlemmer; Ezgi Tasdemir; Martin Uhl; Pierre Génin; Ahmet Civas; Bernhard Ryffel; Jean Kanellopoulos; Jürg Tschopp; Fabrice André; Rosette Lidereau; Nicole M McLaughlin; Nicole M Haynes; Mark J Smyth; Guido Kroemer; Laurence Zitvogel
Journal:  Nat Med       Date:  2009-09-20       Impact factor: 53.440

8.  MABp1, a first-in-class true human antibody targeting interleukin-1α in refractory cancers: an open-label, phase 1 dose-escalation and expansion study.

Authors:  David S Hong; David Hui; Eduardo Bruera; Filip Janku; Aung Naing; Gerald S Falchook; Sarina Piha-Paul; Jennifer J Wheler; Siqing Fu; Apostolia M Tsimberidou; Michael Stecher; Prasant Mohanty; John Simard; Razelle Kurzrock
Journal:  Lancet Oncol       Date:  2014-04-17       Impact factor: 41.316

9.  The inflammasome: a molecular platform triggering activation of inflammatory caspases and processing of proIL-beta.

Authors:  Fabio Martinon; Kimberly Burns; Jürg Tschopp
Journal:  Mol Cell       Date:  2002-08       Impact factor: 17.970

10.  Phosphorylation of the adaptor ASC acts as a molecular switch that controls the formation of speck-like aggregates and inflammasome activity.

Authors:  Hideki Hara; Kohsuke Tsuchiya; Ikuo Kawamura; Rendong Fang; Eduardo Hernandez-Cuellar; Yanna Shen; Junichiro Mizuguchi; Edina Schweighoffer; Victor Tybulewicz; Masao Mitsuyama
Journal:  Nat Immunol       Date:  2013-11-03       Impact factor: 25.606

View more
  38 in total

1.  Combinatorial Detection of Conserved Alteration Patterns for Identifying Cancer Subnetworks.

Authors:  Ermin Hodzic; Raunak Shrestha; Kaiyuan Zhu; Kuoyuan Cheng; Colin C Collins; S Cenk Sahinalp
Journal:  Gigascience       Date:  2019-04-01       Impact factor: 6.524

2.  IL23 induces IL23R recycling and amplifies innate receptor-induced signalling and cytokines in human macrophages, and the IBD-protective IL23R R381Q variant modulates these outcomes.

Authors:  Rui Sun; Matija Hedl; Clara Abraham
Journal:  Gut       Date:  2019-05-16       Impact factor: 23.059

3.  Deletion of Protein Tyrosine Phosphatase Nonreceptor Type 2 in Intestinal Epithelial Cells Results in Upregulation of the Related Phosphatase Protein Tyrosine Phosphatase Nonreceptor Type 23.

Authors:  Sima Ulugöl; Larissa Hering; Roberto Manzini; Ana Montalban Arques; Claudia Gottier; Silvia Lang; Michael Scharl; Marianne R Spalinger
Journal:  Inflamm Intest Dis       Date:  2019-04-10

4.  Protein tyrosine phosphatase nonreceptor type 2 controls colorectal cancer development.

Authors:  Egle Katkeviciute; Larissa Hering; Ana Montalban-Arques; Philipp Busenhart; Marlene Schwarzfischer; Roberto Manzini; Javier Conde; Kirstin Atrott; Silvia Lang; Gerhard Rogler; Elisabeth Naschberger; Vera S Schellerer; Michael Stürzl; Andreas Rickenbacher; Matthias Turina; Achim Weber; Sebastian Leibl; Gabriel E Leventhal; Mitchell Levesque; Onur Boyman; Michael Scharl; Marianne R Spalinger
Journal:  J Clin Invest       Date:  2021-01-04       Impact factor: 14.808

5.  GCN2 drives macrophage and MDSC function and immunosuppression in the tumor microenvironment.

Authors:  Marie Jo Halaby; Kebria Hezaveh; Sara Lamorte; M Teresa Ciudad; Andreas Kloetgen; Bethany L MacLeod; Mengdi Guo; Ankur Chakravarthy; Tiago Da Silva Medina; Stefano Ugel; Aristotelis Tsirigos; Vincenzo Bronte; David H Munn; Trevor J Pugh; Daniel D De Carvalho; Marcus O Butler; Pamela S Ohashi; David G Brooks; Tracy L McGaha
Journal:  Sci Immunol       Date:  2019-12-13

Review 6.  Inflammatory bowel disease: between genetics and microbiota.

Authors:  Nour Younis; Rana Zarif; Rami Mahfouz
Journal:  Mol Biol Rep       Date:  2020-02-21       Impact factor: 2.316

7.  TAFs contributes the function of PTPN2 in colorectal carcinogenesis through activating JAK/STAT signaling pathway.

Authors:  Wei Zhao; Lei Hao; Lizhou Jia; Jinsong Wang; Bin Wang; Yanqiang Huang; Youcai Zhao
Journal:  Am J Cancer Res       Date:  2021-06-15       Impact factor: 6.166

8.  A genetics-led approach defines the drug target landscape of 30 immune-related traits.

Authors:  Hai Fang; Hans De Wolf; Bogdan Knezevic; Katie L Burnham; Julie Osgood; Anna Sanniti; Alicia Lledó Lara; Silva Kasela; Stephane De Cesco; Jörg K Wegner; Lahiru Handunnetthi; Fiona E McCann; Liye Chen; Takuya Sekine; Paul E Brennan; Brian D Marsden; David Damerell; Chris A O'Callaghan; Chas Bountra; Paul Bowness; Yvonne Sundström; Lili Milani; Louise Berg; Hinrich W Göhlmann; Pieter J Peeters; Benjamin P Fairfax; Michael Sundström; Julian C Knight
Journal:  Nat Genet       Date:  2019-06-28       Impact factor: 38.330

9.  Wedelolactone improves the renal injury induced by lipopolysaccharide in HK-2 cells by upregulation of protein tyrosine phosphatase non-receptor type 2.

Authors:  Deyuan Zhi; Meng Zhang; Jin Lin; Pei Liu; Yajun Wang; Meili Duan
Journal:  J Int Med Res       Date:  2021-05       Impact factor: 1.671

10.  Screening and prognostic value of potential biomarkers for ovarian cancer.

Authors:  Huiqin Li; Ming Li; Chunhui Tang; Liang Xu
Journal:  Ann Transl Med       Date:  2021-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.